Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 207
Filter
1.
Eksp Klin Farmakol ; 64(4): 56-8, 2001.
Article in Russian | MEDLINE | ID: mdl-11589113

ABSTRACT

Phytoecdysteroids ecdysteron and turkesteron isolated from Ajuga turkestanica (Rgl.) Brig. decrease the manifestations of uremic intoxication in rats with experimental renal pathology induced by a nephrotoxic mixture (containing uranyl acetate and glycerol). Injected in a dose of 5 mg/kg, the drugs restore glomerular filtration level, favor the disappearance of the albuminuria and normalize urinary sediments. The nephroprotector effect of the phytoecdysteroids studied resembles the action of a steroidal anabolic drug nerobol.


Subject(s)
Ecdysterone/analogs & derivatives , Ecdysterone/therapeutic use , Kidney Diseases/drug therapy , Methandrostenolone/therapeutic use , Phytotherapy , Animals , Diuresis , Ecdysterone/pharmacology , Glycerol , Kidney Diseases/chemically induced , Kidney Diseases/physiopathology , Male , Methandrostenolone/pharmacology , Organometallic Compounds , Proteinuria/drug therapy , Proteinuria/urine , Rats
2.
Eksp Klin Farmakol ; 60(3): 41-4, 1997.
Article in Russian | MEDLINE | ID: mdl-9324397

ABSTRACT

Phytoecdysteroids alpha-ecdysone, 2-desoxyecdysterone, ecdysterone, sileneoside A, and turkesterone isolated from Rhaponticum carthamoides (Willd.) IIjin, Silene brahuica Boiss and Ajuga turkestanica (Rgl.) Repeated administration of brig increased the content of erythrocytes and hemoglobin in the blood of intact rats. The most active of them--ecdysterone, sileneoside A, and, particularly turkesterone, cause also a marked effect on red blood regeneration in hemotoxic phenylhydrazine anemia. In its capacity for simulating erythropoiesis turkesterone resembles the well-known steroidal anabolic drug nerobol.


Subject(s)
Anabolic Agents/pharmacology , Erythropoiesis/drug effects , Methandrostenolone/pharmacology , Phytosterols/pharmacology , Anabolic Agents/administration & dosage , Anabolic Agents/therapeutic use , Anemia, Hemolytic/drug therapy , Animals , Ecdysterone/administration & dosage , Ecdysterone/analogs & derivatives , Ecdysterone/pharmacology , Ecdysterone/therapeutic use , Erythrocyte Count/drug effects , Hemoglobins/metabolism , Methandrostenolone/administration & dosage , Methandrostenolone/therapeutic use , Phenylhydrazines/toxicity , Phytosterols/administration & dosage , Phytosterols/therapeutic use , Rats , Reference Standards , Structure-Activity Relationship
3.
Eksp Klin Farmakol ; 55(3): 61-5, 1992.
Article in Russian | MEDLINE | ID: mdl-1458171

ABSTRACT

The phytoecdisteroids ecdisterone, turkesterone and cyasterone were administered in a dose of 5 mg/kg per os to rats with hepatitis induced by subcutaneous injections of CCl4. Similarly to the anabolic drug nerobol (10 mg/kg), the above agents not only interfere with the manifestation of the hepatic action of CCl4 (in this case the effect of the phytoecdisteroids is more remarkable) but also favour a more rapid normalization, as compared to the control, of functional and metabolic disorders in the liver. The phytoecdisteroids and nerobol noticeably stimulate the recovery of bile secretion, the synthesis of bilirubin and bile acids, cholesterol excretion.


Subject(s)
Antidotes/therapeutic use , Carbon Tetrachloride Poisoning/drug therapy , Chemical and Drug Induced Liver Injury/drug therapy , Liver/drug effects , Methandrostenolone/therapeutic use , Plant Extracts/therapeutic use , Animals , Carbon Tetrachloride Poisoning/complications , Carbon Tetrachloride Poisoning/metabolism , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/metabolism , Drug Evaluation, Preclinical , Ecdysterone/analogs & derivatives , Ecdysterone/therapeutic use , Liver/metabolism , Male , Rats , Stigmasterol/analogs & derivatives , Stigmasterol/therapeutic use
4.
Lab Delo ; (8): 42-4, 1991.
Article in Russian | MEDLINE | ID: mdl-1724507

ABSTRACT

Blood coagulation, immunobiochemical, and clinical characteristics were studied in patients with rheumatic fever running a protracted course treated by combined therapy including nerobol. To assess the therapeutic efficacy of nerobol, the patients were divided into 2 groups: Group 1 (30 patients) were administered combined antirheumatic therapy, Group 2 (30 patients) were administered the same + nerobol in a daily dose of 15 mg for 3-4 weeks. The findings evidence a positive effect of the drug on the status of patients in whom rheumatic fever runs a protracted course: blood procoagulative activity is reduced and anticoagulative activity elevated, blood immunobiochemical and clinical characteristics normalized.


Subject(s)
Blood Coagulation/drug effects , Methandrostenolone/therapeutic use , Rheumatic Diseases/drug therapy , Adolescent , Adult , Female , Humans , Male , Middle Aged , Rheumatic Diseases/blood , Rheumatic Diseases/immunology
6.
Clin Sci (Lond) ; 71(6): 665-73, 1986 Dec.
Article in English | MEDLINE | ID: mdl-3539458

ABSTRACT

Plasma glucose and insulin concentrations were measured during oral (OGTT) and intravenous (IVGTT) glucose tolerance tests in nine patients off- and on-treatment with the anabolic steroid, methandienone (Dianabol). On-treatment, the tolerance tests showed a markedly increased insulin response accompanied by impairment of glucose tolerance, characteristics normally attributed to insulin resistance. However, fasting plasma glucose (FPG) and insulin (FPI) concentrations were significantly reduced, whereas the pattern normally associated with insulin resistance is for both to be raised. IVGTT glucose and insulin profiles were analysed using an algorithm derived from the minimal models of glucose and insulin dynamics originally proposed by R. Bergman and co-workers. Measures for the following parameters were thus obtained: Si, the sensitivity of glucose disposal to insulin; Sg, net insulin independent glucose disposal; phi 1, the integral concentration of insulin delivered during the first phase of insulin secretion relative to the initial increase in glucose concentration above a model-derived threshold; phi 2, the sensitivity of the rate of rise of insulin concentration in the second phase of insulin secretion to the concentration of glucose above a model-derived threshold; kappa, the fractional clearance rate of insulin; and tau 1/2, the insulin half-life. S1 was significantly reduced on treatment by a factor of 4. Sg, phi 1, phi 2 and tau 1/2 were all significantly increased, and kappa was significantly reduced. The increases in Sg and phi 1 both showed significant correlations with the increase in weight on-treatment. The reduction in FPG and FPI can be explained by the combined effects of the increase in Sg and Dianabol-induced resistance to glucagon.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Insulin/blood , Methandrostenolone/therapeutic use , Adult , Blood Glucose/metabolism , Body Weight/drug effects , Female , Glucose Tolerance Test , Humans , Insulin Resistance , Male , Middle Aged , Models, Biological
7.
Article in English | MEDLINE | ID: mdl-2427405

ABSTRACT

The influence of anabolic steroids plus phenformin on the course of disease was studied in patients suffering from occlusive vascular diseases. In arteriosclerosis obliterans of the lower limbs the combined therapy led to a higher percentage of improvement than the control group showed. In coronary heart disease there was also a beneficial effect of this treatment. The drugs were found to exert beneficial clinical effects especially in patients with thrombophlebitis migrans and superficial thrombophlebitis. From the results of this study it is concluded that this therapy may be of clinical value in the treatment of patients with occlusive vascular diseases.


Subject(s)
Arteriosclerosis Obliterans/blood , Coronary Disease/blood , Fibrinolysis/drug effects , Methandrostenolone/therapeutic use , Phenformin/therapeutic use , Stanozolol/therapeutic use , Thrombophlebitis/blood , Adult , Aged , Arteriosclerosis Obliterans/drug therapy , Clinical Trials as Topic , Coronary Disease/drug therapy , Female , Humans , Male , Methandrostenolone/pharmacology , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/complications , Myocardial Infarction/drug therapy , Phenformin/pharmacology , Stanozolol/pharmacology , Thrombophlebitis/drug therapy , Thrombophlebitis/etiology , Varicose Veins/blood , Varicose Veins/complications , Varicose Veins/drug therapy
8.
Article in Russian | MEDLINE | ID: mdl-3811724

ABSTRACT

The results of a 12 month follow-up of 3 groups of age-matched children (7 boys in each group) with an identically malignant course of Duchenne's myodystrophy determined by means of a genealogical analysis are presented. The fastest progression of the disease was observed in children receiving conventional treatment. Untreated children showed slower progression of the disease. In patients on allopurinol treatment the process was somewhat checked or there was some regression of symptomatology.


Subject(s)
Muscular Dystrophies/genetics , Allopurinol/therapeutic use , Child , Combined Modality Therapy , Follow-Up Studies , Humans , Male , Methandrostenolone/therapeutic use , Muscular Dystrophies/diagnosis , Muscular Dystrophies/therapy , Nandrolone/analogs & derivatives , Nandrolone/therapeutic use , Nandrolone Decanoate , Neostigmine/therapeutic use , Syndrome , Vitamins/therapeutic use
10.
Arch Fr Pediatr ; 42(4): 265-71, 1985 Apr.
Article in French | MEDLINE | ID: mdl-4004487

ABSTRACT

The effects of weakly androgenic steroids at minimal doses (norethandrolone 2.5 to 10 mg/day or methandienone 1 mg/day, administered 2 months every trimester) have been studied in 67 patients with Turner syndrome: 37 with 45 XO karyotype and 30 with mosaicism or partial X deletion. Mean bone age at the onset of treatment was 10 4/12 +/- 1 8/12 years, and the mean height retardation, adjusted to parents' height, was 3.7 +/- 1.2 standard deviations. Growth velocity was very significantly increased during the first 3 semesters of treatment. The ratio of bone age to height age, evaluated after 2 years of treatment, did not increase. The adult height reached by 37 treated patients was at the average 1.96 cm higher than that of a control group of 25 adult untreated Turner cases, this difference being not significant. The results varied greatly between individuals, without relation to the type of chromosomal abnormality or the kind and dose of steroid received. The psychological evolution of the treated patients was studied accordingly to their school and/or professional accomplishments. It was satisfactory in most of them. The anabolic treatment and/or the gain in growth velocity during treatment seemed to have positive psychological effect. No side-effects were noticed.


Subject(s)
Growth Disorders/drug therapy , Methandrostenolone/therapeutic use , Norethandrolone/therapeutic use , Turner Syndrome/drug therapy , Body Height/drug effects , Bone Development/drug effects , Child , Female , Follow-Up Studies , Humans , Longitudinal Studies , Methandrostenolone/administration & dosage , Methandrostenolone/adverse effects , Norethandrolone/administration & dosage , Norethandrolone/adverse effects , Time Factors , Turner Syndrome/psychology
12.
Article in Russian | MEDLINE | ID: mdl-4063413

ABSTRACT

Administration of phytoecdisteroides ecdisterone and turkesterone in the dose of 5 mg/kg and anabolic steroid preparation nerobol in the dose 10 mg/kg in rats with experimental diabetes removes the activation of respiration under all metabolic conditions of rats liver mitochondria revealing at given pathology. The normalized effect of phytoecdisteroides on the cells energetic processes is observed on the 7th day of the administration. The same effect of nerobol is revealed at more prolonged (15 days) administration.


Subject(s)
Anabolic Agents/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Mitochondria, Liver/drug effects , Animals , Cholestenones/therapeutic use , Diabetes Mellitus, Experimental/metabolism , Drug Evaluation, Preclinical , Ecdysterone/therapeutic use , Energy Metabolism/drug effects , Male , Methandrostenolone/therapeutic use , Mitochondria, Liver/metabolism , Oxidative Phosphorylation/drug effects , Oxygen Consumption/drug effects , Plant Extracts/therapeutic use , Rats , Time Factors
18.
Kosm Biol Aviakosm Med ; 16(2): 26-9, 1982.
Article in Russian | MEDLINE | ID: mdl-6175791

ABSTRACT

In three series of experiments of 120, 49 and 180 days in duration 36 test subjects were exposed to clinostatic and antiorthostatic hypokinesia. Human requirements for various nutrients were defined under hypokinetic conditions. It was demonstrated that during bed rest exercises together with adequate nutrition and after bed rest certain nutrients can serve as efficient countermeasures against metabolic changes.


Subject(s)
Bed Rest , Nutritional Physiological Phenomena , Adult , Desoxycorticosterone/therapeutic use , Feces/analysis , Humans , Male , Methandrostenolone/therapeutic use , Middle Aged , Nutritional Physiological Phenomena/drug effects , Nutritional Requirements , Pituitary Hormones, Posterior/therapeutic use , Posture , Time Factors , Water-Electrolyte Balance/drug effects
20.
Metabolism ; 30(11): 1076-9, 1981 Nov.
Article in English | MEDLINE | ID: mdl-7026971

ABSTRACT

A two compartment, double-blind, randomized, parallel study was performed comparing methandrostenolone with placebo in the treatment of osteoporosis. The duration of the study was 24 mo. Dependent parameters included total body calcium (TBCa), measured by neutron activation analysis: bone mineral content of the radius (BMC), measured by photon absorptiometry; and total body potassium (TBK), measured by total body counting. A significant increase in TBK occurred in the treated group, primarily in the first 6 mo; thereafter the TBK remained fairly constant. No significant changes in bone mass occurred, except the 6 mo TBCa measurement increased by 11 grams for the methandrostenolone group and decreased by 6 grams for the placebo group (p = .05). Other evidence also suggests that anabolic steroids may not produce sustained uncoupling of bone formation and bone resorption in osteoporosis. If methandrostenolone is capable of producing an increment in bone mass in osteoporosis, it was not readily observable with the sensitivity of the techniques employed in this study


Subject(s)
Body Composition/drug effects , Methandrostenolone/therapeutic use , Osteoporosis/drug therapy , Aged , Calcium/analysis , Clinical Trials as Topic , Humans , Methandrostenolone/adverse effects , Middle Aged , Osteoporosis/metabolism , Potassium/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...